Pre-Test Increasing Access to Improve Outcomes: Exploring the Role of Biosimilars in the Management of Inflammatory Bowel Disease Pre-Test According to a recent report, the availability and use of biosimilar medicines has the potential to reduce drug costs by ________ over the next 5 years . $100 Million $500 Million $100 Billion $500 Billion Unsure Biosimilar __________ is determined by regulatory/legal authorities based on totality of evidence presented. Bioequivalence Extrapolation Interchangeability Pharmacovigilance Unsure Which of the following was the first FDA-approved interchangeable biosimilar product for its reference product: Adalimumab-adbm Adalimumab-aacf Infliximab-abda Infliximab-dyyb Unsure In which of the following clinical scenarios may a biosimilar be considered? If the patient experienced clinically significant antibodies to the reference product If the patient exhibited primary non-response to the reference product Following a drug holiday after previous history of response to the reference product If the patient experienced moderate-to-severe side effects to the reference product Unsure How confident are you in your ability to optimally integrate biosimilars into clinical practice, when appropriate, for the treatment of IBD? Very Confident Confident Somewhat confident Not very confident Not at all confident
